Psychemedics Corporation

    Psychemedics Corporation

    NNASDAQ:PMD
    2.67
    USD
    0.00
    (0.00%)
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    4.8
    5.07
    5.45
    4.99
    7.14
    7.23
    7.75
    6.83
    3.86
    4.46
    4.44
    3.85
    - -
    3.37
    Basic EPS, GAAP
    0.57
    0.72
    0.6
    0.28
    1.22
    1.11
    0.83
    0.28
    -0.7
    -0.12
    -0.19
    -0.72
    - -
    -0.32
    Free Cash Flow per Basic Share
    0.17
    0.83
    -0.58
    0.52
    1.33
    1.45
    1.22
    0.48
    -0.92
    0.04
    0.83
    -0.29
    - -
    0.14
    Dividend per Share
    0.6
    0.6
    0.6
    0.6
    0.6
    0.6
    0.69
    0.72
    0.18
    0.05
    0.21
    0.14
    - -
    - -
    Book Value per Share
    -1.36
    -1.23
    -1.22
    -1.53
    -0.9
    -0.38
    -0.24
    -0.67
    -1.55
    -1.7
    -2.07
    -2.92
    - -
    -3.19
    Tangible Book Value per Share
    2.13
    2.32
    2.4
    2.16
    2.86
    3.39
    3.4
    3.05
    2.26
    2.19
    1.9
    1.16
    - -
    0.88
    Basic Weighted Avg Shares
    5
    5
    5
    5
    5
    5
    6
    6
    6
    6
    6
    6
    - -
    6
    Sales/Revenue/Turnover
    25
    27
    29
    27
    39
    40
    43
    38
    21
    25
    25
    22
    20
    20
    Operating Margin (%)
    19.57
    21.24
    16.06
    5.45
    25.94
    20.55
    17.83
    7.96
    -28.4
    0.84
    -4.29
    -13.22
    -9.62
    -9.62
    Depreciation Expense
    1
    1
    1
    2
    2
    3
    3
    3
    4
    4
    3
    3
    2
    2
    Net Income, GAAP
    3
    4
    3
    2
    7
    6
    5
    2
    -4
    -1
    -1
    -4
    -2
    -2
    Effective Tax Rate (%)
    39.65
    34.38
    30.8
    - -
    33.06
    25.14
    40.1
    49.54
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    11.81
    14.16
    10.98
    5.6
    17.13
    15.42
    10.74
    4.09
    -18.07
    -2.67
    -4.29
    -18.8
    -9.45
    -9.45
    Working Capital
    7
    7
    7
    5
    6
    10
    10
    7
    6
    4
    4
    2
    2
    2
    LT Debt
    - -
    - -
    5
    4
    2
    2
    1
    4
    7
    3
    2
    1
    - -
    - -
    Total Equity
    11
    12
    13
    12
    16
    19
    19
    17
    13
    12
    11
    7
    5
    5
    Return on Invested Capital (%)
    27.12
    32.24
    20.86
    - -
    36.83
    28.91
    20.75
    6.84
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    -42.16
    -55.61
    -94.05
    - -
    -346.44
    -5,188.99
    570.94
    119.67
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    ST Debt
    1
    1
    1
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    1
    1
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    6
    6
    6
    Market Capitalization
    14
    13
    13

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    Total Current Assets
    6
    6
    5
    Cash, Cash Equivalents & STI
    1
    1
    1
    Accounts Receivable, Net
    3
    3
    3
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    4
    4
    3
    Payables & Accruals
    3
    3
    2
    ST Debt
    1
    1
    1
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -6.66%
    -20.19%
    -23.11%
    Free Cash Flow
    114.26%
    248.71%
    -151.44%
    Net Income, GAAP
    4.73%
    -28.4%
    -55.2%
    Sales/Revenue/Turnover
    -1.42%
    -9.75%
    -10.92%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    7
    7
    7
    6
    25
    2023
    6
    6
    6
    5
    22
    2024
    5
    5
    5
    4
    20

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    0.01
    -0.06
    -0.02
    -0.12
    -0.19
    2023
    -0.07
    -0.13
    -0.36
    - -
    -0.72
    2024
    -0.12
    -0.14
    -0.09
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    0.07
    0.07
    0.21
    2023
    - -
    - -
    - -
    - -
    0.14
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Psychemedics Releases 2026 Workforce Insights Report

    • globenewswire.com

      Psychemedics Releases 2025 Workforce Insights Report

    • globenewswire.com

      Psychemedics Named “Most Innovative Drug Testing Company of the Year”

    • globenewswire.com

      Psychemedics Corporation Announces Reverse and Forward Stock Split

    • globenewswire.com

      Psychemedics Corporation Reports Third Quarter 2024 Financial Results

    • globenewswire.com

      Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing

    • globenewswire.com

      Psychemedics Corporation Reports Second Quarter 2024 Financial Results

    • globenewswire.com

      Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock

    • globenewswire.com

      Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing

    • globenewswire.com

      Psychemedics Corporation Reports First Quarter 2024 Financial Results

    • globenewswire.com

      Psychemedics Corporation Reports 2023 Financial Results

    • globenewswire.com

      Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

    • globenewswire.com

      Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

    • globenewswire.com

      Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    • globenewswire.com

      Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    • globenewswire.com

      Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

    • globenewswire.com

      Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    • globenewswire.com

      Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • globenewswire.com

      Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    • globenewswire.com

      Psychemedics Corporation Announces CEO Succession Plan